Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research
Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research
复制标题
DOI：
10.1158/1078-0432.ccr-10-2656
复制
发表时间：
2011-06-15
影响因子：
11.5
通讯作者：
Drake, Charles G.
中科院分区：
文献类型：
--
作者：
Gulley, James L.;Drake, Charles G.
在最近的临床试验表明，这种疫苗可以在统计上显著和临床上有意义地改善转移性去势耐受前列腺癌患者的总体生存率-与化疗相比副作用基本上有限-之后，人们对治疗性癌症疫苗的兴趣激增。其中一项试验导致了西普鲁切尔-T的注册，这是第一个被批准用于癌症患者的治疗性疫苗。在这篇综述中，我们强调了来自临床试验的新模式，这些模式表明需要更合适的患者群体(即较低的肿瘤体积和较少侵袭性的疾病)和终点(即总存活率)来单独进行免疫治疗研究，并对这些发现进行生物学上可信的解释。我们还探讨了正在进行和计划中的将治疗性疫苗与其他方式相结合的研究的基本原理。最后，我们试图将这些发现放在实际的临床背景下，并为未来的研究提出肥沃的领域。尽管我们的讨论集中在前列腺癌上，但我们讨论的概念很可能也广泛适用于其他癌症的免疫治疗。临床癌症研究；17(12)；3884-91。(C)2011年AACR。
A surge of interest in therapeutic cancer vaccines has arisen in the wake of recent clinical trials suggesting that such vaccines can result in statistically significant and clinically meaningful improvements in overall survival-with substantially limited side effects compared with chemotherapy-in patients with metastatic castration-resistant prostate cancer. One of these trials led to the registration of sipuleucel-T, the first therapeutic vaccine to be approved for cancer patients. In this review we highlight emerging patterns from clinical trials that suggest a need for more-appropriate patient populations (i.e., with lower tumor volume and less-aggressive disease) and endpoints (i.e., overall survival) for studies of immunotherapy alone, as well as biologically plausible explanations for these findings. We also explore the rationale for ongoing and planned studies combining therapeutic vaccines with other modalities. Finally, we attempt to put these findings into a practical clinical context and suggest fertile areas for future study. Although our discussion focuses on prostate cancer, the concepts we address most likely have broad applicability to immunotherapy for other cancers as well. Clin Cancer Res; 17(12); 3884-91. (C) 2011 AACR.